-
14404-10Reversibly inhibits dihyroorotate dehydrogenase, the rate-limiting step in the de novo synthesis of pyrimidines, preventing DNA synthesis of activated lymphocytes (IC<sub>50</sub>s = 0.09, 3.
-
14404-25Reversibly inhibits dihyroorotate dehydrogenase, the rate-limiting step in the de novo synthesis of pyrimidines, preventing DNA synthesis of activated lymphocytes (IC<sub>50</sub>s = 0.09, 3.
-
14404-5Reversibly inhibits dihyroorotate dehydrogenase, the rate-limiting step in the de novo synthesis of pyrimidines, preventing DNA synthesis of activated lymphocytes (IC<sub>50</sub>s = 0.09, 3.
-
A0099-1 mgMas antagonist that inhibits signaling by angiotensin (1-7), preventing vasodilation and insulin sensitization.
-
A0099-2 mgMas antagonist that inhibits signaling by angiotensin (1-7), preventing vasodilation and insulin sensitization.
-
A0099-5 mgMas antagonist that inhibits signaling by angiotensin (1-7), preventing vasodilation and insulin sensitization.
-
10012588-10A sodium channel blocker with high-affinity and selectivity for inhibiting human Nav1.8 sodium channels (IC50 = 8 nM when stimulated at half-maximal inactivation and IC50 = 79 nM at a resting state) dose dependently reduces behavioral responses in
-
10012588-100A sodium channel blocker with high-affinity and selectivity for inhibiting human Nav1.8 sodium channels (IC50 = 8 nM when stimulated at half-maximal inactivation and IC50 = 79 nM at a resting state) dose dependently reduces behavioral responses in
-
10012588-5A sodium channel blocker with high-affinity and selectivity for inhibiting human Nav1.8 sodium channels (IC50 = 8 nM when stimulated at half-maximal inactivation and IC50 = 79 nM at a resting state) dose dependently reduces behavioral responses in
-
10012588-50A sodium channel blocker with high-affinity and selectivity for inhibiting human Nav1.8 sodium channels (IC50 = 8 nM when stimulated at half-maximal inactivation and IC50 = 79 nM at a resting state) dose dependently reduces behavioral responses in
-
20060-10A potent and selective competitive antagonist of the P2X<sub>7</sub> receptor.
-
20060-25A potent and selective competitive antagonist of the P2X<sub>7</sub> receptor.